By targeting VAP-1, this method may allow precise localization and evaluation of systemic vascular inflammation, potentially reducing reliance on inconclusive multimodal approaches and enhancing diagnostic strategies and therapeutic management in GCA. The gene discussed is AOC3; the disease is temporal arteritis.